2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Metabolomics profiling reveals distinct, sex-specific signatures in the serum and brain metabolomes in the mouse models of Alzheimer’s disease

      Preprint
      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          INTRODUCTION:

          Increasing evidence suggests that metabolic impairments contribute to early Alzheimer’s disease (AD) mechanisms and subsequent dementia. Signals in metabolic pathways conserved across species provides a promising entry point for translation. METHODS: We investigated differences of serum and brain metabolites between the early-onset 5XFAD and late-onset LOAD1 (APOE4.Trem2*R47H) mouse models of AD to C57BL/6J controls at six months of age.

          RESULTS:

          We identified sex differences for several classes of metabolites, such as glycerophospholipids, sphingolipids, and amino acids. Metabolic signatures were notably different between brain and serum in both mouse models. The 5XFAD mice exhibited stronger differences in brain metabolites, whereas LOAD1 mice showed more pronounced differences in serum.

          DISCUSSION:

          Several of our findings were consistent with results in humans, showing glycerophospholipids reduction in serum of APOE4 carriers and replicating the serum metabolic imprint of the APOE4 genotype. Our work thus represents a significant step towards translating metabolic dysregulation from model organisms to human AD.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: not found

          Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

          The apolipoprotein E type 4 allele (APOE-epsilon 4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE-epsilon 4 alleles in 42 families with late onset AD. Thus APOE-epsilon 4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE-epsilon 4 was virtually sufficient to cause AD by age 80.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation.

            Mutations in the genes for amyloid precursor protein (APP) and presenilins (PS1, PS2) increase production of beta-amyloid 42 (Abeta42) and cause familial Alzheimer's disease (FAD). Transgenic mice that express FAD mutant APP and PS1 overproduce Abeta42 and exhibit amyloid plaque pathology similar to that found in AD, but most transgenic models develop plaques slowly. To accelerate plaque development and investigate the effects of very high cerebral Abeta42 levels, we generated APP/PS1 double transgenic mice that coexpress five FAD mutations (5XFAD mice) and additively increase Abeta42 production. 5XFAD mice generate Abeta42 almost exclusively and rapidly accumulate massive cerebral Abeta42 levels. Amyloid deposition (and gliosis) begins at 2 months and reaches a very large burden, especially in subiculum and deep cortical layers. Intraneuronal Abeta42 accumulates in 5XFAD brain starting at 1.5 months of age (before plaques form), is aggregated (as determined by thioflavin S staining), and occurs within neuron soma and neurites. Some amyloid deposits originate within morphologically abnormal neuron soma that contain intraneuronal Abeta. Synaptic markers synaptophysin, syntaxin, and postsynaptic density-95 decrease with age in 5XFAD brain, and large pyramidal neurons in cortical layer 5 and subiculum are lost. In addition, levels of the activation subunit of cyclin-dependent kinase 5, p25, are elevated significantly at 9 months in 5XFAD brain, although an upward trend is observed by 3 months of age, before significant neurodegeneration or neuron loss. Finally, 5XFAD mice have impaired memory in the Y-maze. Thus, 5XFAD mice rapidly recapitulate major features of AD amyloid pathology and may be useful models of intraneuronal Abeta42-induced neurodegeneration and amyloid plaque formation.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              2018 Alzheimer's disease facts and figures

              (2018)
                Bookmark

                Author and article information

                Journal
                bioRxiv
                BIORXIV
                bioRxiv
                Cold Spring Harbor Laboratory
                22 December 2023
                : 2023.12.22.573059
                Affiliations
                [1 ]The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT 06032 USA
                [2 ]Department of Psychiatry and Behavioral Sciences, Duke University, 905 W Main St, Durham, NC 27701, USA
                [3 ]Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764 Oberschleißheim, Germany
                [4 ]Department of Physiology and Biophysics, Institute for Computational Biomedicine, Englander Institute for Precision Medicine, Weill Cornell Medicine, 1305 York Ave, New York, NY 10022, USA
                [5 ]The Jackson Laboratory, 600 Main St, Bar Harbor, ME 04609, USA
                [6 ]Duke Institute of Brain Sciences, Duke University, 308 Research Dr, Durham, NC 27710, USA
                [7 ]Department of Medicine, Duke University, DUMC Box 104002, Durham, North Carolina 27710, USA
                Author notes
                [*]

                Equal contributions

                Correspondence: gregory.carter@ 123456jax.org , Gregory Carter, The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609
                Author information
                http://orcid.org/0000-0002-4666-0923
                http://orcid.org/0000-0003-4734-3791
                http://orcid.org/0000-0003-0565-6474
                http://orcid.org/0000-0002-2834-8186
                Article
                10.1101/2023.12.22.573059
                10769366
                38187571
                fcfcea36-b5f3-415b-a394-0162dc385d53

                This work is licensed under a Creative Commons Attribution 4.0 International License, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.

                History
                Funding
                Funded by: The National Institute on Aging
                Award ID: U54 AG054345
                Funded by: Alzheimer’s Disease Metabolomics Consortium (ADMC), NIA, FNIH
                Award ID: R01AG046171
                Award ID: RF1AG051550
                Award ID: RF1AG057452
                Award ID: R01AG059093
                Award ID: RF1AG058942
                Award ID: U01AG061359
                Award ID: U19AG063744
                Award ID: DAOU16AMPA
                Funded by: National Institute of Aging of the National Institutes of Health, NIA
                Award ID: 1U19AG063744
                Award ID: R01AG069901-01
                Funded by: Alzheimer’s Disease Neuroimaging Initiative (ADNI), National Institutes of Health, DOD ADNI
                Award ID: U01 AG024904
                Award ID: W81XWH-12-2-0012
                Funded by: NIA, Duke University, Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago
                Award ID: 3R01AG046171-02S2
                Funded by: NIA, Illinois Department of Public Health (ROSMAP), Translational Genomics Research Institute (genomic)
                Award ID: P30AG10161
                Award ID: R01AG15819
                Award ID: R01AG17917
                Award ID: R01AG30146
                Award ID: R01AG36042
                Award ID: RC2AG036547
                Award ID: R01AG36836
                Award ID: R01AG48015
                Award ID: RF1AG57473
                Award ID: U01AG32984
                Award ID: U01AG46152
                Award ID: U01AG46161
                Award ID: U01AG61356
                Categories
                Article

                metabolomics,alzheimer’s disease,5xfad,apoe4,animal models

                Comments

                Comment on this article